A Phase 3 interventional study of Esomeprazole and Esomeprazole in Reflux Esophagitis, sponsored by AstraZeneca. Completed at 41 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2010-12-20.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Esophagitis, Peptic by AstraZeneca — none open to participants now, none under way, none of them phase 3. Esophagitis, Peptic · AstraZeneca.
Among the 12 studies in Esophagitis, Peptic by AstraZeneca, this one is one of 2 that started in 2007, is one of 5 in phase 3, and was the 2nd registered.
83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.
Browse Esophagitis, Peptic studies →None of the 12 studies in Esophagitis, Peptic by AstraZeneca is open now. The open studies under Esophagitis, Peptic, anywhere →
Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 602 is above the median of 135 across 60 interventional studies indexed under Esophagitis, Peptic.
Median enrollment 114 across the 8 interventional studies, 2,643 across the 4 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Esophagitis, Peptic by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by assessment of presence/absence of Reflux Esophagitis at Week 8 according to the Los Angeles classification .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Esomeprazole 20mg
Drug: Esomeprazole
Esomeprazole 40mg
Drug: Esomeprazole
Omeprazole 20mg
Drug: Omeprazole
20mg once daily
Also known as: Nexium
40 mg once daily
Also known as: Nexium
20mg once daily
Also known as: Prilosec
Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification".
Los Angeles classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C, Grade D). The subjects who were definitely diagnosed to have RE classified into LA classification Grade A, B, C or D based on the EGD on Visit 1 were randomised. A subject classified into LA classification Grade O was considered no reflux esophagitis. The definitions of each grade are: Grade A (Mucosal break \< 5 mm in length), Grade B (Mucosal break \> 5mm), Grade C (Mucosal break continuous between \> 2 mucosal folds) and Grade D (Mucosal break \>75% of esophageal circumference).
Time frame: 8 weeks
Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 4 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification
Los Angeles classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C and Grade D). The subjects who were definitely diagnosed to have RE classified into LA classification Grade A, B, C or D based on the EGD on Visit 1 were randomised. A subject classified into LA classification Grade O was considered no reflux esophagitis. The definitions of each grade are: Grade A (Mucosal break \< 5 mm in length), Grade B (Mucosal break \> 5mm), Grade C (Mucosal break continuous between \> 2 mucosal folds) and Grade D (Mucosal break \>75% of esophageal circumference).
Time frame: 4 weeks
First subject enrolled on 11 December 2007. Last subject completed on 12 December 2008.
| Milestone | Experimental: Esomeprazole 40mg | Experimental: Esomeprazole 20mg | Comparator: Omeprazole 20mg |
|---|---|---|---|
| Started | 191 | 190 | 191 |
| Completed | 179 | 176 | 180 |
| Not completed | 12 | 14 | 11 |
| Withdrew: Adverse event | 1 | 3 | 4 |
| Withdrew: Withdrawal by subject | 3 | 9 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 |
| Withdrew: Protocol violation | 5 | 2 | 3 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Doctor's judgement | 1 | 0 | 0 |
| Withdrew: Moved away | 1 | 0 | 0 |
Los Angeles classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C, Grade D). The subjects who were definitely diagnosed to have RE classified into LA classification Grade A, B, C or D based on the EGD on Visit 1 were randomised. A subject classified into LA classification Grade O was considered no reflux esophagitis. The definitions of each grade are: Grade A (Mucosal break \< 5 mm in length), Grade B (Mucosal break \> 5mm), Grade C (Mucosal break continuous between \> 2 mucosal folds) and Grade D (Mucosal break \>75% of esophageal circumference).
| participants | Experimental: Esomeprazole 40mg | Experimental: Esomeprazole 20mg | Comparator: Omeprazole 20mg |
|---|---|---|---|
| Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification". | 171 | 165 | 166 |
Los Angeles classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C and Grade D). The subjects who were definitely diagnosed to have RE classified into LA classification Grade A, B, C or D based on the EGD on Visit 1 were randomised. A subject classified into LA classification Grade O was considered no reflux esophagitis. The definitions of each grade are: Grade A (Mucosal break \< 5 mm in length), Grade B (Mucosal break \> 5mm), Grade C (Mucosal break continuous between \> 2 mucosal folds) and Grade D (Mucosal break \>75% of esophageal circumference).
| participants | Experimental: Esomeprazole 40mg | Experimental: Esomeprazole 20mg | Comparator: Omeprazole 20mg |
|---|---|---|---|
| Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 4 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification | 141 | 147 | 143 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Esomeprazole 40mg | — | 0/190 (0%) | 12/190 (6.3%) |
| Experimental: Esomeprazole 20mg | — | 1/189 (0.5%) | 9/189 (4.8%) |
| Comparator: Omeprazole 20mg | — | 1/190 (0.5%) | 16/190 (8.4%) |
| Event | Experimental: Esomeprazole 40mg | Experimental: Esomeprazole 20mg | Comparator: Omeprazole 20mg |
|---|---|---|---|
| BronchopneumoniaInfections and infestations | 0/190 | 1/189 | 0/190 |
| Influenza Like IllnessGeneral disorders | 0/190 | 1/189 | 0/190 |
| GastroenteritisInfections and infestations | 0/190 | 0/189 | 1/190 |
| Event | Experimental: Esomeprazole 40mg | Experimental: Esomeprazole 20mg | Comparator: Omeprazole 20mg |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 10/190 | 6/189 | 10/190 |
| DiarrhoeaGastrointestinal disorders | 2/190 | 3/189 | 6/190 |
| Age, Customized(Participants) | Experimental: Esomeprazole 40mg | Experimental: Esomeprazole 20mg | Comparator: Omeprazole 20mg | Total |
|---|---|---|---|---|
| < 65 years | 127 | 135 | 126 | 388 |
| 65 - 74 years | 47 | 36 | 44 | 127 |
| >= 75 years | 16 | 18 | 20 | 54 |
| Missing | 1 | 1 | 1 | 3 |
| Sex/Gender, Customized(Participants) | Experimental: Esomeprazole 40mg | Experimental: Esomeprazole 20mg | Comparator: Omeprazole 20mg | Total |
|---|---|---|---|---|
| Male | 139 | 137 | 134 | 410 |
| Female | 51 | 52 | 56 | 159 |
| Missing | 1 | 1 | 1 | 3 |
The record gives a start of Dec 2007 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole